Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Gneiss, C; Reindl, M; Lutterotti, A; Ehling, R; Egg, R; Khalil, M; Berger, T; Deisenhammer, F.
Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.
Mult Scler. 2004; 10(5):507-510 Doi: 10.1191/1352458504ms1074oa
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Khalil Michael
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: It has been reported that in some patients with MS who develop neutralizing antibodies (NAbs) against interferon beta (IFNbeta), antibody levels can initially increase and then decrease thereafter even when treatment is continued. OBJECTIVE: To determine whether NAb titre correlates with time to reversion to NAb negativity in patients with multiple sclerosis (MS). METHODS: Twenty-eight patients with MS who were NAb-positive during treatment with one of the currently available IFNbetas were included in this retrospective study. NAb titres were determined by the myxovirus resistance protein A induction assay. Patients were considered NAb-positive if they had at least two consecutive samples with titres of > or = 20 neutralizing units (NU). Reversion to NAb-negative status was defined as two consecutive negative samples (NAb titre of < 20 NU) after NAb positivity. RESULTS: When measured two years after treatment initiation, a NAb titre of < 75 NU had a 91.7% sensitivity and a 87.5% specificity for reversion to NAb negativity in the following two years (after a total of four years of treatment). In addition, somewhat surprisingly, patients whose serum converted to NAb-negative generally developed peak NAb titres earlier than patients who remained NAb-positive (mean time of first detection was 21 versus 38 months, respectively). CONCLUSION: The NAb titre might support treatment decisions in patients with MS whose test results are positive for NAbs.
Find related publications in this database (using NLM MeSH Indexing): Adjuvants, Immunologic - administration and dosage; Antibodies - blood; Humans - blood; Interferon-beta - administration and dosage; Multiple Sclerosis - drug therapy; Neutralization Tests - drug therapy; Predictive Value of Tests - drug therapy; Retrospective Studies - drug therapy
Find related publications in this database (Keywords): interferon beta; multiple sclerosis; neutralizing antibodies